Itolizumab

立即咨询

Itolizumab

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

1116433-11-4

包装与价格：

包装	价格(元)
1mg	电议
5mg	电议

产品名称

Anti-Human CD6 Recombinant Antibody

产品介绍

Itolizumab (Anti-Human CD6 Recombinant Antibody) 是一种人源化重组抗 CD6单克隆抗体 (MAb)，靶向 CD6 的细胞外 SRCR 远端结构域 1。Itolizumab 可减少 T 细胞增殖并抑制促炎细胞因子的产生，例如 INF-γ、TNFα 和 IL-6。Itolizumab 可用于银屑病、类风湿性关节炎 (RA)、COVID-19 的研究。

生物活性

Itolizumab (Anti-HumanCD6Recombinant Antibody) is a humanized recombinantanti-CD6monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 ofCD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα andIL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19^[1]^[2]^[3].

IC₅₀& Target

CD6^[1]

体外研究
(In Vitro)

Itolizumab (100 μg/mL) inhibits T cell proliferation^[4].
Itolizumab (0-100 μg/mL) inhibits Treg polarization and enhances acquisition of Th1 phenotype in PBMCs^[4].
Itolizumab (40 μg/mL) reduces CD26^hiCD161+ CD8+ T cells during culture of PBMCs overnight^[5].
Itolizumab (40 μg/mL, 3-12 days) reduces the expression of IL-17 and IFN-γ in PBMCs stimulated in Th17 polarizing conditions^[6].

体内研究
(In Vivo)

Itolizumab (60 μg or 300μg, i.p., everyday) shows therapeutic efficiency in a humanized xenograft mouse model of Graft Vs Host Disease (GVHD)^[7].

Animal Model:	Humanized xenograft mice, generated by intravenous transfer human PBMCs into 6-8 weeks old NOD/SCID IL2rγ-null (NSG)^[7]
Dosage:	60 μg or 300μg
Administration:	Intraperitoneal injection (i.p.), prior to PBMC transplantation.
Result:	Decreased mortality compared to the vehicle (100% vs. 10%).

CAS 号

1116433-11-4

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.